In a nutshell This study investigated the risk factors for ischemic or hemorrhagic stroke recurrence and the impact of antiplatelet therapy in patients with intracranial hemorrhage (ICH; brain bleed). The data showed that the risk of stroke recurrence is high in these patients. Hypertension (high blood pressure) is a risk factor for ischemic and...
Read MoreEvaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.
In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...
Read MoreEvaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.
In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...
Read MoreEvaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.
In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...
Read MoreEvaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.
In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...
Read More